VRCA vs. MNPR, ACRS, IMRX, TRDA, HRTX, ACIU, SLS, GNFT, IPHA, and EPRX
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Monopar Therapeutics (MNPR), Aclaris Therapeutics (ACRS), Immuneering (IMRX), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), AC Immune (ACIU), SELLAS Life Sciences Group (SLS), GENFIT (GNFT), Innate Pharma (IPHA), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs. Its Competitors
Monopar Therapeutics (NASDAQ:MNPR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Monopar Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals' return on equity of 0.00% beat Monopar Therapeutics' return on equity.
Monopar Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.
1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Monopar Therapeutics presently has a consensus target price of $69.57, suggesting a potential upside of 92.13%. Verrica Pharmaceuticals has a consensus target price of $80.00, suggesting a potential upside of 1,429.64%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Monopar Therapeutics.
In the previous week, Monopar Therapeutics had 10 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 12 mentions for Monopar Therapeutics and 2 mentions for Verrica Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.86 beat Verrica Pharmaceuticals' score of 0.58 indicating that Monopar Therapeutics is being referred to more favorably in the media.
Summary
Monopar Therapeutics beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 9/4/2025 by MarketBeat.com Staff
Free VRCA Stock Alerts